HAI is pleased to address the 152nd session of the Executive Board on the critical topic of substandard and falsified medicines; access to effective and safe medicines is indispensable and remains a challenge for far too many.

We believe that the member state mechanism is the correct venue for an agile cooperation between parties.

The scourge of spurious medicines can and must be stopped; greater efforts should be aimed at increasing the technical capacity of national authorities to detect and disrupt the flow of substandard products, raise awareness among the public about the unregulated sale of health goods and facilitate the work of health professionals by securing the supply of quality-assured medicines to health facilities.

-End-

February 2023